Leukemia News

In this video, Michael Choi, MD, discusses the results of the phase 3 Alliance study, pertaining to chronic lymphocytic leukemia, presented at ASCO Annual Meeting.

Researchers at Tisch Cancer Center have created innovative models of acute myeloid leukemia, offering an unprecedented resource for studying this deadly blood cancer, according to a study published in Blood Cancer Discovery.

In this video, Eunice Wang, MD, discussed a retrospective analysis looking at outcomes of chimeric antigen receptor T-cell therapy for patients diagnosed with B-cell acute lymphoblastic leukemia, presented at ASCO Annual Meeting.

In this video, Eunice Wang, MD, discussed an abstract relating to new chimeric antigen receptor T-cell therapies treating acute lymphocytic leukemia, presented at ASCO Annual Meeting.

In this video, Eunice Wang, MD, discussed the results of the phase 3 IMerge study, pertaining to low- or intermediate-risk myelodysplastic syndrome, presented at ASCO Annual Meeting.

Seattle Children’s Hospital has paused the phase 1 PLAT-08 trial of SC-DARIC33 after one patient treated with the investigational chimeric antigen receptor T-cell therapy died.

ASCO Chief Medical Officer Julie R. Gralow, MD, FACP, FASCO, urged members of Congress to take action on cancer drug shortages, which she described as the worst she has witnessed during her 30-year career in oncology.

In this edition, prior authorization linked delay in prescription fills; disparities in access to specialized cancer centers; ‘new potential treatment option’ for advanced chronic lymphocytic leukemia and more.

In this video, Eunice Wang, MD, discussed the results of the phase 3 COMMANDS study, pertaining to low-risk myelodysplastic syndrome, presented at ASCO Annual Meeting.

CHICAGO — Seventy-six percent of adults with relapsed or refractory B-cell acute lymphoblastic leukemia achieved complete response to treatment with obecabtagene autoleucel, interim results of the pivotal phase 2 FELIX trial showed.